Drospirenone-Only Emergency Contraceptive Pill
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Emergency
- Development Stage: Phase II
- Developer(s)/researcher(s): University of Colorado, Denver
Details
- API: Drospirenone
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Delay
- Regimen: On Demand
- MPT: Not Potential MPT
- Promising Attributes: Drospirenone has the potential for less-restricted efficacy in overweight and obese users than other existing oral EC methods.
Product Status
While a Ph II trial was registered on Clinicaltrials.gov, there is no indication that the study initiated. Record will be monitored and moved to inactive when appropriate.
History
2022: The Society of Family Planning awards researchers at the University of Colorado Denver a small grant to support clinical research on the potential use of a drospirenone-only pill as emergency contraceptive.
2022: Researchers indicate intent to enroll 35 participants in dose-range finding study on the novel EC method, with planned study initiation in 2023.